Efgartigimod Clinical Trials

5 actively recruiting trials across 3 locations

Pipeline

Phase 3: 2Phase 4: 1

Top Sponsors

argenx2
University Health Network, Toronto1
Janssen Research & Development, LLC1
Centre Hospitalier Universitaire de Nice1

Indications

Cancer5
Myasthenia Gravis3
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy1
Efgartigimod1
Myasthenia Gravis, Generalized1

Other2 trials

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

Phase 4

Seronegative Myasthenia Gravis - Efgartigimod IV

Phase 3

San Francisco, California1 trial

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,

Farmington, Connecticut1 trial

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

University of Connecticut

Phase 3

Morgantown, West Virginia1 trial

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

United BioSource LLC

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.